Pinealon (Glu-Asp-Arg, EDR) — a Khavinson short peptide

Overview

Pinealon is a synthetic tripeptide with the structure L-glutamyl-L-aspartyl-L-arginine (Glu-Asp-Arg; three-letter code EDR). It belongs to the family of so-called Khavinson short peptides, low-molecular-weight di-, tri- and tetrapeptides designed as "core" fragments of larger tissue peptide preparations (polypeptide complexes). Pinealon is regarded as a synthetic analogue of a bioregulatory motif associated with peptide extracts of the pineal gland and nervous tissue, and is studied mainly as a neurotropic agent in cell and animal models. This text is strictly reference and research-oriented (research-use-only, RUO): it describes chemistry, molecular mechanisms and the published research record, and contains no recommendations for human use.

Discovery and background

The concept of short peptide bioregulators grew out of a long-running program on tissue peptide preparations (cytomedins and cytogens) initiated by V. Kh. Khavinson's school at the St. Petersburg Institute of Bioregulation and Gerontology. The idea was that the biological activity of complex polypeptide extracts is largely reproduced by short amino-acid sequences that can be synthesized chemically and characterized. In this paradigm EDR emerged as a "neuronal" tripeptide motif, and the tetrapeptide AEDG (Ala-Glu-Asp-Gly, Epitalon) as its "pineal" relative. An early experimental foundation for Pinealon was the demonstration that EDR increases neuronal viability in culture by suppressing free-radical levels and activating proliferative processes ^[1]. Subsequent work framed a broader hypothesis: short peptides act not as classical receptor ligands but as regulators of gene expression, capable of reaching nuclear DNA ^[2][6].

Structure and physicochemistry

Pinealon is a linear tripeptide with free N- and C-termini (H-Glu-Asp-Arg-OH). The empirical formula of the free peptide is C15H26N6O8, and its average molecular mass is about 418.4 g/mol. The molecule combines two acidic residues (glutamate and aspartate) bearing two side-chain carboxyl groups with one strongly basic arginine residue carrying a guanidinium group; at physiological pH the peptide is zwitterionic and carries a pronounced dipolar and charge pattern. This amphoteric architecture (the compact juxtaposition of negatively charged carboxylates and a positively charged guanidinium) is thought to be key to interaction with polar and charged surfaces, notably the phosphate backbone and nucleotide bases of DNA ^[3][5]. The arginine guanidinium can form bifurcated hydrogen bonds with guanine in the major groove, while the carboxylates coordinate with other bases and amines, giving the short peptide an unexpectedly selective "reading" of particular dinucleotide contexts.

Molecular mechanism

The central working hypothesis for Pinealon's mechanism is direct peptide-DNA interaction followed by epigenetic/transcriptional modulation. In experiments with fluorescently labeled peptides, EDR-type short peptides were shown to penetrate HeLa cells and accumulate in the nucleus and nucleolus, while binding in vitro specifically to deoxyribooligonucleotides and double-stranded DNA ^[2]. A functional signature of this binding was that site-specific interaction of short peptides with DNA modulates the activity of eukaryotic endonucleases, that is, the peptide alters the accessibility or conformation of specific sequences ^[3]. A computational-structural screen using molecular modeling systematized these observations, delineating structural motifs of peptide binding to double-stranded DNA and showing that even di- and tripeptides have recognizable preferences for particular groove sequences ^[5]. For EDR itself, an integrative analysis linked its activity to the regulation of gene expression and protein synthesis relevant to neuronal physiology ^[4].

Signaling and downstream effects

At the level of cellular response, Pinealon is described as a redox and transcriptional modulator rather than an activator of a specific membrane receptor. In a primary neuronal model, EDR lowered intracellular reactive oxygen species (ROS) and increased cell viability, accompanied by activation of proliferative signals ^[1]. This antioxidant component is consistent with the effects of the related tetrapeptide AEDG, which prevented oxidative stress in a model of induced fibroblast aging, a shared trait of the short-peptide family ^[9]. At the transcriptional level, Khavinson short peptides alter the expression of a broad set of genes; integrative work describes modulation of genes involved in neuronal differentiation, antioxidant defense and maintenance of proliferative potential ^[4][7]. The proposed causal logic is: nuclear penetration → site-specific binding to promoter/regulatory regions → altered chromatin accessibility and transcription rate → a shift of the proteomic profile toward pro-survival and differentiation programs ^[6][7].

Preclinical research findings

The most compelling primary preclinical result for Pinealon is the increase in neuronal cell viability through suppression of free-radical burden and activation of proliferation in culture ^[1]. Cellular studies of penetration and DNA binding provided a mechanistic underpinning for these effects ^[2][3]. In the broader family context, short peptides have been studied in models of neurodegeneration and aging: analysis of EDR linked it to the regulation of genes implicated in Alzheimer's disease pathogenesis ^[4], and in human mesenchymal stem cell cultures short peptides modulated the age-related gene-expression profile ^[10]. Neurotropic interest in pineal/neuronal peptides is also fueled by models of impaired brain development: in a rat model of prenatal hyperhomocysteinemia, impairments of memory formation and shifts in hippocampal biogenic amine content were documented, precisely the type of neurochemical vulnerability that peptide-bioregulator research targets for correction ^[8]. It should be stressed that these data are at the preclinical/model level and are not evidence of clinical efficacy.

Clinical / human research

For the Pinealon tripeptide specifically, the peer-reviewed body of controlled human clinical trials is limited; most published data remain at the level of cell and animal models and mechanistic work ^[1][2][4]. The Khavinson short-peptide family as a whole has been discussed in the gerontology literature in the context of hypotheses about peptide regulation of aging, but high-quality randomized data on EDR specifically have not yet been established. Any claims of therapeutic benefit in humans would therefore be premature; this material presents the human dimension only as a direction for future research, not as guidance.

Pharmacokinetics and metabolism

As a small hydrophilic tripeptide with free termini, Pinealon is expected to undergo rapid proteolytic hydrolysis by plasma and tissue aminopeptidases and carboxypeptidases, so its plasma half-life is measured in minutes rather than hours. This is a typical property of short peptides and one reason researchers often attribute biological activity not to prolonged systemic presence but to a rapid "signaling" contact and its hydrolysis products. The paradox is that despite low metabolic stability in blood, labeled short peptides are nonetheless detected in the nucleus of cultured cells ^[2], supporting the notion of direct intracellular/nuclear targeting rather than classical systemic pharmacokinetics of a receptor ligand. Detailed validated ADME profiles (bioavailability, distribution, renal excretion of fragments) for EDR are lacking in the peer-reviewed literature, and this remains an open analytical question.

Related compounds and analogues

Pinealon belongs to a family in which each short peptide is associated with a particular tissue "profile." Its closest relatives are: AEDG (Ala-Glu-Asp-Gly, Epitalon), a tetrapeptide linked to the pineal gland and telomerase/antioxidant themes ^[9]; KE (Lys-Glu, Vilon), an immunotropic dipeptide; AED (Ala-Glu-Asp, Vesugen), a vascular motif; KEDW (Lys-Glu-Asp-Trp), pancreatic. Common to all are their brevity, amphotericity and the hypothesis of DNA-mediated gene regulation ^[5][6]. Comparative computational analysis showed that even minor compositional changes (a single amino acid) shift the preferred DNA binding motifs, consistent with the idea of "tissue specialization" of short peptides ^[5][7].

Analytical characterization

The identity and purity of Pinealon in a research context are established by standard peptide analytics. Mass spectrometry, or MS (ESI-MS or MALDI-TOF) confirms a molecular mass of about 418.4 Da and the sequence via fragmentation (MS/MS, b/y ions). Analytical reversed-phase HPLC (C18, water/acetonitrile gradient with 0.1% TFA, UV detection at 210–220 nm on the peptide bond) quantifies chromatographic purity; for such a polar, charge-rich peptide, weak retention is possible, so ion-pairing additives or HILIC are often used. Amino-acid analysis after acid hydrolysis confirms the Glu:Asp:Arg ratio, and capillary electrophoresis confirms charge homogeneity. Key impurities monitored are residual protecting groups, deletion/truncation sequences and deamidation products (conversion of Glu/Asp motifs). Supplier-grade research batches typically state a specification such as "HPLC purity ≥ 98%" together with a confirmatory MS spectrum.

Handling, reconstitution chemistry and storage

Pinealon is supplied as a lyophilized powder, the most storage-stable form. The lyophilizate is kept tightly closed, in a dry environment, protected from light; long-term storage recommends freezing (−20 °C or below), while short-term storage is possible at +2…+8 °C. Because the two acidic residues are sensitive to deamidation/hydrolysis, repeated freeze-thaw cycles are avoided. For experiments the peptide is reconstituted in bacteriostatic or sterile water; owing to the polar, charged nature of EDR it is readily soluble in aqueous buffers, and organic co-solvents are usually unnecessary (DMSO is used only if needed for problematic batches). Reconstituted solutions are aliquoted and stored frozen to minimize proteolytic and chemical degradation. All of the above pertains solely to laboratory handling chemistry of the reagent and is not guidance for use in humans or animals.

Research applications and model systems

In research practice, Pinealon is used primarily as a probe tool for studying peptide-DNA interactions and epigenetic regulation by short ligands. Typical model systems include: primary neuronal cultures and neuronal cell lines for viability and ROS assessment ^[1]; HeLa cells and cell-free systems with deoxyribooligonucleotides for mapping nuclear accumulation and DNA binding ^[2][3]; human mesenchymal stem cell cultures for analysis of age-related transcriptome shifts ^[10]; and computational molecular docking/dynamics platforms for predicting groove binding motifs ^[5]. Broader animal models of neurodevelopment and neurodegeneration (such as prenatal hyperhomocysteinemia) provide context for hypotheses about neuroprotective regulation ^[8], while comparison with AEDG and the rest of the family allows the concept of tissue specificity of short peptides to be tested ^[4][6][7][9]. Overall, the research value of Pinealon today lies not in clinical use but in its being a convenient, well-characterized model for testing the "short peptide as epigenetic regulator" hypothesis.